Medical Device Company Lazurite™ to Relocate its Headquarters to Accommodate Growth

Medical device and technology company Lazurite Holdings LLC announced today the relocation and expansion of its headquarters from Cleveland to a new office space in suburban Warrensville Heights, Ohio, to advance the operations and growth of the company. The new office space is located at 4700 Richmond Road.

“We are thrilled to relocate our headquarters to Warrensville Heights as the area will provide the foundation for our continued growth initiatives going forward,” said Leah Brownlee, President. “We selected Warrensville Heights because of its attractive economic development incentive program, convenient location, and because the space already had the electronic labs set up that we require, not to mention it lives up to being a ‘Friendly City.’”

Raymon Turner, Community Development Manager for the city stated, “We are extremely pleased to welcome Lazurite Holdings LLC to our city. They are on the cutting edge of medical technology with the creation of their fully wireless, minimally invasive camera system platform. With our close proximity to both University Hospitals and the Cleveland Clinic we see this as a wonderful opportunity to bolster the medical research and training happening right now in our community.”

Expanding to 6,000 square feet from its current 3,000 square feet will provide the necessary infrastructure for the company to continue to build on its current momentum. Lazurite currently employs 15 people and plans to onboard at least 10 employees in 2022 primarily in research and development and sales roles.

Earlier this year, Lazurite’s ArthroFree™ Wireless Surgical Camera won the prestigious inaugural ACE Award for Innovation from the American Orthopaedic Society for Sports Medicine. The company is taking steady steps on its plan to launch its ArthroFree wireless arthroscopic camera system next year. Lazurite plans to submit its premarket notification this year and expects to receive FDA approval to launch in the first half of 2022.

The ArthroFree™ wireless arthroscopic camera system has not yet received FDA clearance and is not currently approved for human use. It is not intended for commercial distribution; orders cannot be accepted at this time.

 

SourceLazurite

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version